unexplained recurrent spontaneous abortion
Conditions
Interventions
experimental group:Cyclosporine
Sponsors
Obstetrics & Gynecology Hospital of Fudan University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: The subjects should meet all of the following criteria before they can participate in this study. 1. Healthy, willing to participate in this study, willing to take medication and follow-up according to plan, and willing to sign the informed consent; 2. Aged 20-40 and consistented with a history of unexplained recurrent abortion; 3. The test of hcg in urine was positive after the couple have sexual intercourse for 14 days; 4. TORCH IgM (-); 5. The antibody of blood type for ABO <1: 128, for RH is normal; 6. Hysteroscopy or H.S.G: At least one side of the fallopian tube is unobstructed, and the shape of uterine cavity is normal whatever through ways of surgery, medication and other means; 7. The test of routine semen examination for husband is basically normal or normal fertilization after treatment; 8. The karyotype of the couple is normal.
Exclusion criteria
Exclusion criteria: The subjects are not allowed to participate in this study if they meet any of the following criteria: 1. Patients who have suffered from the severe diseases in respiratory system (such as tuberculosis, etc.), endocrine, nervous system, cardiovascular system, digestive system or urogenital system; 2. Patients who have suffered from the contraindications or allergies of CsA; 3. Patients with smoking cigarettes more than the number of 20 for one day; 4. Patients with genital tract virus infection or cervical slack or genital malformations (such as double uterus, etc.), endocrine abnormalities (such as diabetes, etc.) or chromosomal abnormalities; 5. Patients with the history of miscarriage caused by embryo chromosomal abnormalities two or more times; 6. Unwilling to sign informed consent or follow the doctor's order; 7. HBV, HCV, HIV, HPV or infectious diseases such as syphilis, influenza, gonorrhea, etc.; 8. Patients with severe endometrial disease such as atypical hyperplasia; 9. BMI > 30; 10. Patients who were diagnosed as autoimmune diseases (including but not limited to rheumatoid arthritis, systemic lupus erythematosus, Inflammatory myopathy, systemic sclerosis, Sjgren's syndrome, antiphospholipid syndrome, etc.); 11. Patients who have became pregnant successfully by embryo transfer or showed fetal heart or germ in B-ultrasound; 12. Patients who have a history of thrombosis or have been cured; 13. Patients with mental illness or other reasons that can't cooperate with treatment; 14. Patients with heart, liver, kidney and other important organ diseases seriously or tumors or cancer; 15. The investigator judges that the patient's condition is not suitable for the research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| live birth rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum markers;The rate of successful pregnancy more than 3 months;Neonatal and infant evaluation;Immune indexes; | — |
Countries
China
Contacts
Public ContactDajin Li
Obstetrics & Gynecology Hospital of Fudan University
Outcome results
None listed